Global Leading Market Research Publisher QYResearch announces the release of its latest report “Long-acting Muscarinic Antagonists (LAMAs) – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Long-acting Muscarinic Antagonists (LAMAs) market, including market size, share, demand, industry development status, and forecasts for the next few years.
Addressing core industry needs: COPD patients require sustained bronchodilation to manage symptoms and reduce exacerbations – but short-acting agents provide only 4–6 hour relief. Long-acting muscarinic antagonists (LAMAs) solve this with once-daily dosing (24-hour duration) by blocking M3 receptors in airway smooth muscle. Key drivers include COPD prevalence, GOLD guideline recommendations, and generic LAMA availability.
The global market for Long-acting Muscarinic Antagonists (LAMAs) was estimated to be worth US$ 2,115 million in 2025 and is projected to reach US$ 2,765 million, growing at a CAGR of 4.0% from 2026 to 2032. In 2024, the average price was approximately US$ 11.67 per unit, with total sales volume of around 175 million units.
Long-acting muscarinic antagonists (LAMAs) are a class of bronchodilators widely used in the management of chronic obstructive pulmonary disease (COPD). They work by blocking M3 muscarinic receptors in the airway smooth muscles, providing sustained bronchodilation. Compared with short-acting agents, LAMAs have a prolonged duration of action, typically lasting for 24 hours, which allows once-daily dosing and improves lung function as well as patients’ quality of life. Representative drugs include tiotropium, usually administered through dry powder inhalers or nebulizers.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6098353/long-acting-muscarinic-antagonists–lamas
Market Segmentation & Key Players
The Long-acting Muscarinic Antagonists (LAMAs) market is segmented as below:
Leading Suppliers: Boehringer Ingelheim, Teva Pharmaceutical, Novartis, The Menarini Group, Covis Pharma, Zentiva, Alfasigma, Gebro-Pharma, Kohl Medical, Cipla, GSK, Zhejiang Xianjun Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group, Nanchang Helioeast Technology.
Segment by Type: Aclidinium | Glycopyrrolate | Tiotropium | Umeclidinium | Others
Segment by Application: Asthma | COPD | Others
Exclusive Industry Insights
Discrete DPI/nebulizer formulation: LAMAs are formulated as micronized API (<5μm) blended with lactose (DPIs) or aqueous solutions (nebulizers). Receptor binding: LAMAs dissociate slowly from M3 receptors, providing prolonged bronchodilation (24+ hours).
Technical differentiation – LAMA molecules:
| Molecule | Brand | Device | Once-Daily | Generic Available |
|---|---|---|---|---|
| Tiotropium | Spiriva | DPI (HandiHaler) / Respimat | Yes | Yes (EU, US 2025) |
| Umeclidinium | Incruse | DPI (Ellipta) | Yes | No (patent until 2028) |
| Glycopyrrolate | Seebri | DPI (Breezhaler) / Nebulizer | Yes | Partial |
| Aclidinium | Tudorza | DPI (Pressair) | Twice daily | No |
Recent 6-month data (Oct 2025 – Mar 2026):
- COPD dominates (92% of revenue), with minimal asthma use (step-up therapy).
- Tiotropium largest segment (58% revenue), generic entry in US (2025) accelerating.
- Triple therapy (LAMA + LABA + ICS) fastest-growing (CAGR 6.5%), preferred for frequent exacerbators.
User case – National health service (UK, 1.2 million COPD patients): Formulary preference for generic tiotropium DPI (post-patent) reduced annual LAMA spend by US$ 65M (38% savings). Adherence rates unchanged (72%), exacerbation rates stable over 18 months.
GOLD 2025 guideline recommendations:
| COPD Group | Initial Therapy | Escalation |
|---|---|---|
| A (low risk, low symptoms) | Bronchodilator (SABA or LAMA) | - |
| B (low risk, more symptoms) | LABA + LAMA | Triple therapy |
| E (high risk) | LABA + LAMA | Triple therapy (ICS added) |
Application insights: COPD (92%) – maintenance therapy for moderate-to-very severe COPD (GOLD Groups B/E). Asthma (6%) – add-on therapy for uncontrolled asthma (off-label, step 5). Others (2%) – off-label uses.
Regional snapshot: North America leads with 48% revenue share (higher branded prices). Europe holds 28% (generic penetration accelerating). Asia-Pacific fastest-growing (CAGR 5.2%), driven by COPD diagnosis improvement and aging populations.
Conclusion
The LAMA market is mature but stable, driven by COPD prevalence, generic tiotropium entry, and triple therapy adoption. Success depends on DPI device usability, patent expiration management, and combination product development. The projected US$ 2.77 billion market by 2032 appears achievable.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
